DETERMINANTS OF LIPID-LEVELS AMONG CHILDREN WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN NORWAY

被引:36
|
作者
TONSTAD, S [1 ]
LEREN, TP [1 ]
SIVERTSEN, M [1 ]
OSE, L [1 ]
机构
[1] UNIV OSLO, ULLEVAAL HOSP, DEPT MED GENET, N-0407 OSLO, NORWAY
关键词
FAMILIAL HYPERCHOLESTEROLEMIA; LDL RECEPTOR MUTATION; APO E; DIETARY INTAKE; CHILDREN;
D O I
10.1161/01.ATV.15.8.1009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Three founder mutations have been discovered among individuals with familial hypercholesterolemia (FH) in Norway: FHElverum and FHSvartor, predicted to be null alleles, and FHC210G, predicted to disrupt the secondary structure of the ligand-binding domain. To clarify the effect of these and other mutations on lipid levels and parental history of premature cardiovascular disease, we examined 164 boys and girls ages 6 to 16 years with heterozygous FH. Among all children, serum cholesterol levels of the FH parent, percent body fat, pubertal stage, and serum cholesterol levels of the non-FH parent, but not apo E polymorphism, were significant determinants of LDL cholesterol levels in a stepwise multiple regression equation and explained 40% (95% confidence interval [CI], 25% to 55%) of the variance in LDL cholesterol. Among boys, percent body fat, dietary sucrose, and apo E genotype determined 31% (95% CI, 14% to 49%) of the variance in triglyceride levels; whereas among girls, only percent body fat was associated with triglyceride levels. Percent body fat was not associated with LDL cholesterol or triglyceride levels in the FHC210G group. The children's and FH parents' lipid levels and premature cardiovascular disease among parents were similar among the nullallele and defective-protein groups and in those with an undetected mutation. These data confirm that the phenotypic expression of FH in childhood is influenced by modifiable lifestyle characteristics and by genetic factors other than the underlying mutation and raise the possibility that body fatness may interact with genotype in determining lipid levels.
引用
收藏
页码:1009 / 1014
页数:6
相关论文
共 50 条
  • [21] Nailfold capillaroscopy reveals early peripheral microcirculation abnormalities in children affected by heterozygous familial hypercholesterolemia
    Martino, Francesco
    Barilla, Francesco
    Martino, Eliana
    Placanica, Giuseppe
    Paravati, Vincenzo
    Bassareo, Pier Paolo
    MICROVASCULAR RESEARCH, 2023, 148
  • [22] UNDERREPRESENTATION OF NON-WHITE CHILDREN IN TRIALS OF STATINS IN CHILDREN WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Belay, Brook
    Racine, Andrew D.
    Belamarich, Peter F.
    ETHNICITY & DISEASE, 2009, 19 (02) : 166 - 171
  • [23] Maternal inheritance does not predict cholesterol levels in children with familial hypercholesterolemia
    Narverud, Ingunn
    van Lennep, Jeanine Roeters
    Christensen, Jacob J.
    Versmissen, Jorie
    Gran, Jon Michael
    Iversen, Per Ole
    Aukrust, Pal
    Halvorsen, Bente
    Ueland, Thor
    Ulven, Stine M.
    Ose, Leiv
    Veierod, Marit B.
    Sijbrands, Eric
    Retterstol, Kjetil
    Holven, Kirsten B.
    ATHEROSCLEROSIS, 2015, 243 (01) : 155 - 160
  • [24] Heterozygous familial hypercholesterolemia in children: Low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations
    Torres, AL
    Moorjani, S
    Vohl, MC
    Gagne, C
    Lamarche, B
    Brun, LD
    Lupien, PJ
    Despres, JP
    ATHEROSCLEROSIS, 1996, 126 (01) : 163 - 171
  • [25] Genetic Identification of Homozygous Familial Hypercholesterolemia by Long-Read Sequencing Among Patients With Clinically Diagnosed Heterozygous Familial Hypercholesterolemia
    Chaudhry, Ahsen
    Trinder, Mark
    Vesely, Kristin
    Cermakova, Lubomira
    Jackson, Linda
    Wang, Jian
    Hegele, Robert A.
    Brunham, Liam R.
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2023, 16 (02): : E003887
  • [26] How much further do we need to decrease LDL cholesterol levels in heterozygous familial hypercholesterolemia?
    Harada-Shiba, Mariko
    ATHEROSCLEROSIS, 2019, 284 : 218 - 220
  • [27] Statin therapy and secretory phospholipase A2 in children with heterozygous familial hypercholesterolemia
    Braamskamp, Marjet J. A. M.
    Tsimikas, Sotirios
    Wiegman, Albert
    Kastelein, John J. P.
    Hutten, Barbara A.
    ATHEROSCLEROSIS, 2013, 229 (02) : 404 - 407
  • [28] A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia
    Langslet, Gisle
    Breazna, Andrei
    Drogari, Euridiki
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (05) : 1153 - 1162
  • [29] Salivary cholesterol level does not reflect cholesterolemia in children with heterozygous familial hypercholesterolemia
    Fricaudet, Marianne
    Di Filippo, Mathilde
    Moulin, Philippe
    Nony, Severine
    Peron, Marie Anais
    Brignot, Helene
    Feron, Gilles
    Sage, Cedric
    Poinsot, Pierre
    Loras, Remi Duclaux
    Croyal, Mikael
    Charriere, Sybil
    Peretti, Noel
    NUTRITION CLINIQUE ET METABOLISME, 2023, 37 (03): : 162 - 167
  • [30] Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels
    Funabashi, Sayaka
    Kataoka, Yu
    Hori, Mika
    Ogura, Masatsune
    Doi, Takahito
    Noguchi, Teruo
    Harada-Shiba, Mariko
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (16):